Decision/Risk Analysis · Brisbane, CA · Founded 2014 · Privately Held (backing)
Developer of a multi-omics platform designed to detect cancer at an early stage through a routine blood draw. Freenome is based in Brisbane, CA and was founded in 2014. It is valued at about $2.2 billion as of Oct 2026, set by institutional fund marks. It has raised $1.4 billion across 3 recorded rounds; the latest was a $240 million pipe round in Dec 2025.
PMV mark · valuation
$2.2B
Oct 2026
Priced at
—
Total raised
$1.4B
Last round
PIPE
Dec 2025
No prints on record
No secondary trades in Freenome shares have been recorded yet. When market activity lands it appears here as monthly aggregates and, for platform-recorded trades, dated prints.
Pro members can request priority coverage with a 48-hour turnaround.
Secondary marks are indicative month-end price levels observed across secondary-market trading venues — a level, not a trade — and are the market input to the PrivateMarketView mark. Private share prices aren’t published anywhere. Aggregate figures combine multiple reporting channels — direct participant reports, platform transactions, third-party market intelligence — at monthly granularity. Individually dated prints are a Pro feature and are shown only for transactions recorded on our own platform. Third-party-reported trades are never republished individually, at any tier. Verified prints (✓) have been confirmed against a second source. Prints marked SPV or Forward reflect the structure’s pricing, which can differ from direct share transfers of Freenome stock.
